Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda to Introduce New Performance-Based Incentive Programs for Board of Directors, Senior Execs
April 30, 2014
- Kissei Taps Morozumi as New President, COO
April 30, 2014
- Chugai Discontinues Multinational PIII of Onartuzumab for Lung Cancer
April 30, 2014
- Hisamitsu Begins PI of Transdermal Schizophrenia Treatment in US
April 30, 2014
- Novel Anticancer Agent Trabectedin Meets Primary Endpoint of PFS in PII: Taiho
April 25, 2014
- MTPC Names Masayuki Mitsuka as New President
April 24, 2014
- Yoshindo, Lupin to Establish JV to Develop Etanercept Biosimilar, Start Clinical Trial in FY2014
April 24, 2014
- Ethical Drug Sales Jump 11.0% to Record 240.1 Billion Yen in 2013: Boehringer Japan
April 24, 2014
- Astellas Aims to Dominate SGLT-2 Inhibitor Market with Suglat
April 23, 2014
- Lilly Japan Starts PIII Study of Tadalafil for DMD Treatment
April 22, 2014
- Metal Objects Found in Voltaren Suppositories in Aichi Pref.: Novartis
April 22, 2014
- Nihon Generic Obtains Teva’s Manufacturing Plant, Eyeing Expansion of Production Capacity
April 22, 2014
- Entry into Japan Biosimilar Market Will Take Time, Says BI Chairman
April 21, 2014
- PIII Trial of Asthma Drug Benralizumab Kicks Off in Japan: Kyowa Kirin
April 21, 2014
- NBI Postpones Launch of Anticancer Drug Giotrif until May 7
April 21, 2014
- Kyowa Kirin, Amgen of US Terminate License Agreement for Mogamulizumab
April 21, 2014
- Astellas Launches Japan’s 1st SGLT-2 Inhibitor Suglat
April 18, 2014
- Sanofi Aims to Top SGLT-2 Inhibitor Market with Apleway
April 18, 2014
- “MRs’ Manners” Are Opening Theme in Panel Discussion Held by MREAC
April 18, 2014
- Sales of Diovan Fell 22% in 3rd Quarter of FY2013; Overall Growth of ARB Market Could Fall Short of Expectations
April 18, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…